A5066548173- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging Techniques and Applications
- Medical Imaging and Pathology Studies
- Radiation Therapy and Dosimetry
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Effects of Radiation Exposure
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Advanced Radiotherapy Techniques
- Ovarian cancer diagnosis and treatment
- Immunotherapy and Immune Responses
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Particle accelerators and beam dynamics
- Prostate Cancer Treatment and Research
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Radioactive Decay and Measurement Techniques
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Innovations in Medical Education
- Photocathodes and Microchannel Plates
University of Gothenburg
2014-2024
Sahlgrenska University Hospital
1993-2002
Chalmers University of Technology
2002
The α-emitter <sup>211</sup>At labeled to a monoclonal antibody has proven safe and effective in treating microscopic ovarian cancer the abdominal cavity of mice. Women complete clinical remission after second-line chemotherapy for recurrent carcinoma were enrolled phase I study. aim was determine pharmacokinetics assessing absorbed dose normal tissues investigating toxicity. <b>Methods:</b> Nine patients underwent laparoscopy 2–5 d before therapy; peritoneal catheter inserted, inspected...
Bioconjugates used in internal radiotherapy exhibit heterogeneous distributions organs and tumors, implying a risk of nonuniform dose distribution therapeutic applications using α-particle emitters. Tools are required that provide data on the activity for estimation absorbed suborgan level. The α-camera is quantitative imaging technique developed to detect α-particles tissues ex vivo. aim this study was evaluate characteristics system exemplify its potential use development...
Eliminating microscopic residual disease with α-particle radiation is theoretically appealing. After extensive preclinical work α-particle–emitting <sup>211</sup>At, we performed a phase I trial intraperitoneal therapy in epithelial ovarian cancer using <sup>211</sup>At conjugated to MX35, the antigen-binding fragments—F(ab′)<sub>2</sub>—of mouse monoclonal antibody. We now present clinical outcome data and toxicity long-term follow-up individual absorbed dose estimations. <b>Methods:</b>...
The use of nanobodies (Nbs) as vehicles in targeted alpha therapy (TAT) has gained great interest because their excellent properties. They combine high vivo affinity and specificity binding with fast kinetics. This research investigates a novel that combines the α-particle emitter astatine-211 (211At) anti-HER2 Nb 2Rs15d to selectively target HER2+ cancer cells. Two distinctive radiochemical methodologies are investigated using three different coupling reagents. first method uses reagents,...
<sup>211</sup>At-labeled tumor-specific antibodies have long been considered for the treatment of disseminated cancer. However, limited availability nuclide and poor efficacy labeling procedures at clinical activity levels present major obstacles to their use. This study evaluated a procedure direct astatination production levels. <b>Methods:</b> The monoclonal antibody trastuzumab was conjugated with reagent <i>N</i>-succinimidyl-3-(trimethylstannyl)benzoate, immunoconjugate labeled...
The role of radiation-induced bystander effects in radiation therapy remains unclear. With renewed interest with α-particle emitters, and their potential for sterilizing disseminated tumor cells (DTCs), it is critical to determine the contribution overall response so they can be leveraged maximum clinical benefit. <b>Methods:</b> Female <i>Foxn1<sub>nu</sub></i> athymic nude mice were administered 0, 50, or 600 kBq/kg <sup>223</sup>RaCl<sub>2</sub> create conditions. At 24 hours after...
To enhance targeting efficacy in the radioimmunotherapy of disseminated cancer, several pretargeting strategies have been developed. In pretargeted radioimmunotherapy, tumor is with a modified monoclonal antibody that has an affinity for both antigens and radiolabeled carriers. this work, we aimed to synthesize evaluate poly-L-lysine-based effector molecules applications based on tetrazine trans-cyclooctene reaction using 211At targeted alpha therapy 125I as surrogate imaging radionuclides...
To characterize the expression of membrane transporter NaPi2b and antigen targeted by MX35 antibody in ovarian tumor samples. The current interest to develop monoclonal based therapy cancer targeting emphasizes need for detailed knowledge characterization pattern this protein. For majority patients with carcinoma risk being diagnosed late stages extensive loco-regional spread disease is substantial, which stresses improved therapeutic agents. gene protein SLC34A2/NaPi2b were analyzed tissues...
Studies combining immune checkpoint inhibitors with external beam radiation have shown a therapeutic advantage over each modality alone. The purpose of these works is to evaluate the potential targeted delivery high LET tumor microenvironment via an inhibitor.The impact protein concentration on distribution 111In-DTPA-anti-PD-L1-BC, 111In-antibody conjugate PD-L1, was evaluated in immunocompetent mouse model breast cancer. 225Ac-DOTA-anti-PD-L1-BC by both macroscale (ex vivo biodistribution)...
Abstract To facilitate multicentre clinical studies on targeted alpha therapy, it is necessary to develop an automated, on-site procedure for conjugating rare, short-lived, alpha-emitting radionuclides biomolecules. Astatine-211 one of the few nuclides with appropriate chemical and physical properties use in therapies cancer. Due very short range emitted α-particles, this therapy particularly suited treating occult, disseminated cancers. Astatine not intrinsically tumour-specific; therefore,...
Purpose Pretargeted radioimmunotherapy (PRIT) is a multi-step method of selectively delivering high doses radiotherapy to tumor cells while minimizing exposure surrounding tissues. Yttrium-90 (90Y) and lutetium-177 (177Lu) are two the most promising beta-particle emitting radionuclides used for radioimmunotherapy, which despite having similar chemistries differ distinctly in terms radiophysical features. These differences may have important consequences absorbed dose tumors normal organs....